about
The thrombopoietin receptor, c-Mpl, is a selective surface marker for human hematopoietic stem cells.Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic StrategiesAn overview of stem cell research and regulatory issuesBone marrow stem and progenitor cell contribution to neovasculogenesis is dependent on model system with SDF-1 as a permissive trigger.Mapping hematopoiesis in a fully regenerative vertebrate: the axolotlFunctional integration of acute myeloid leukemia into the vascular niche.The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis.Virotherapy using myxoma virus prevents lethal graft-versus-host disease following xeno-transplantation with primary human hematopoietic stem cells.Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trial.Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries.The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrowFactors affecting the turnaround time for manufacturing, testing, and release of cellular therapy products prepared at multiple sites in support of multicenter cardiovascular regenerative medicine protocols: a Cardiovascular Cell Therapy Research NeMulticenter cell processing for cardiovascular regenerative medicine applications: the Cardiovascular Cell Therapy Research Network (CCTRN) experience.PARP1 is required for chromosomal translocations.Marrow cell therapies for cardiovascular diseases.A critical analysis of clinical outcomes reported in stem cell trials for acute myocardial infarction: some thoughts for design of future trials.High rate of uncaptured myelodysplastic syndrome cases and an improved method of case ascertainment.Endothelial cell derived angiocrine support of acute myeloid leukemia targeted by receptor tyrosine kinase inhibition.Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitroAldehyde dehydrogenase activity as a functional marker for lung cancer.Optimization of a myeloid cell transfusion strategy for infected neutropenic hosts.Acute myeloid leukemia in the vascular niche.Myxoma virus targets primary human leukemic stem and progenitor cells while sparing normal hematopoietic stem and progenitor cells.Tandem Autologous Stem Cell Transplantation for Multiple Myeloma Patients Based on Response to Their First Transplant-A Prospective Phase II StudySelective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus.Distinct hematopoietic progenitor compartments are delineated by the expression of aldehyde dehydrogenase and CD34.Response to letter regarding article, "a detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b and clonogenic capacity as biomarkers for clinical outcomes".Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma.Bone marrow-derived stem-cell repopulation contributes minimally to the Type II pneumocyte pool in transplanted human lungs.Adult human hematopoietic cells provide functional hemangioblast activity.Developmental differences in megakaryocyte maturation are determined by the microenvironment.Bone marrow contributes to epithelial cancers in mice and humans as developmental mimicry.Continuous Rural-Urban Coding for Cancer Disparity Studies: Is It Appropriate for Statistical Analysis?Bone marrow transdifferentiation in brain after transplantation: a retrospective studyCharacteristics of thawed autologous umbilical cord bloodOvercoming chronic myeloid leukemia stem cell resistance to imatinib by also targeting JAK2Radiation alone for solid tumors and the questionable development of therapy-related myelodysplastic syndromesFishing for myelodysplastic syndromes finds uncaptured cases by state cancer registries: Need for more resourcesSafety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromesCC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia
P50
Q25257167-7EE64919-F1DA-4D4C-870F-996B1651D655Q26751959-EE081E48-569B-4238-971D-F06ED63DE937Q28198165-48C8762F-27C8-4FA2-88A2-0F592132F9BCQ30491509-2E2286FF-D260-4714-A170-7F67CB9F59D6Q34077771-D4B7B799-FAAF-4FBF-B45D-35207ED749B9Q34207361-0E41CCB7-42B0-47B5-9143-3235317F0702Q34337681-729444D0-7D2E-4451-AFA5-983C1D0B311DQ34384975-587D0138-84C2-4DE1-AB80-C18C82FA945AQ34807168-4D893F82-180F-4D7B-A21B-F5B4D40C0A46Q35127977-3820CD11-7CE6-49AA-BC36-5B1CF97E1A4AQ35571892-050E4C16-50FA-4F7C-A7EA-F3800BB8CD36Q35968757-CBD8AF24-51D9-40AD-B0ED-D2295CFE3AFCQ36694473-41EA9FFD-FDC7-4824-92CD-35F6E3F87832Q36873293-8F4CE95E-275E-428C-84A3-5F14C7A01AC3Q37122491-1CB89351-5B5B-42EF-A21B-52CC71239F9EQ37238552-E15B9819-43E2-43E0-AC13-869552D5565DQ38166487-698D24C4-1CB2-4D79-850F-EB9FBBE31B17Q38851537-4130FB87-B1EF-4B2F-913C-A09C792CD50BQ39395568-5A4EF407-78F8-4C7B-BB50-7FAAE5C17C90Q39925109-8E945BE0-FEDE-436A-9672-50B78966C690Q40198543-07CBFC33-72AE-4564-9776-62E6BE6539CDQ40950337-150E3C2C-3647-48AC-9B40-E2C41D5BFF15Q41052462-639F8D7E-174F-48EB-BCE8-CB0775EB666BQ41901542-4A11C9B0-8B19-498F-9599-31BA5CA6694DQ42144185-729A09EB-973F-4008-AADD-45A7630C482BQ42161087-D1DA0550-67CD-494F-870F-3CF5F01F30ADQ43058119-6449C020-ADCC-49A6-80D8-4EF1550B0D69Q44492261-750DA7E8-6101-466C-9891-C2D67600AADBQ44578109-E57947AB-CE4C-4A65-84EE-D01794ADC4BAQ44582213-4B7FB17A-F32E-4093-82A6-C9ED9040F7E6Q50751778-62D65E69-C853-4FF3-B171-5F9F532D02D5Q51986997-169EB998-8EAE-4A27-9715-EE4A64DB81ABQ64119363-1D185F9C-736B-4302-AF5C-DA260EAA97DFQ80035903-2F04AD98-AC32-4A95-8715-8ECDE639FA95Q83414722-DDC1425E-7846-4059-96E0-5474B2EB3CC9Q86214493-81C184B2-1651-40FE-99FF-FFDDB90FC20DQ87374786-7C9A7180-1958-4864-B660-1010B0CF35C3Q87469040-D2FD99E4-21D6-45AF-9724-F239381F311BQ90823245-EDEC8CCD-09D0-4F69-B55B-CDD7B687779AQ90981512-827F7BB0-DF9A-4324-BD80-3D54F5E6A043
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Christopher R Cogle
@nl
Christopher R Cogle
@sl
Christopher R. Cogle
@en
Christopher R. Cogle
@es
type
label
Christopher R Cogle
@nl
Christopher R Cogle
@sl
Christopher R. Cogle
@en
Christopher R. Cogle
@es
prefLabel
Christopher R Cogle
@nl
Christopher R Cogle
@sl
Christopher R. Cogle
@en
Christopher R. Cogle
@es
P1053
H-1746-2016
P106
P1153
6506513647
P21
P31
P3829
P496
0000-0001-5422-6863